ARTRYA LIMITED — Capital/Financing Update 2021

Nov 23, 2021

==> picture [596 x 15] intentionally omitted <==

==> picture [92 x 19] intentionally omitted <==

Coronary Artery Disease. We see you.

ASX ANNOUNCEMENT

24 November 2021

Pre-quotation disclosure

Reference is made to the initial public offering ( Offer ) of fully paid ordinary shares ( Shares ) in Artrya Limited (ACN 624 005 741) (ASX:AYA) ( Artrya ) pursuant to the original prospectus issued by Artrya and lodged with the Australian Securities and Investments Commission ( ASIC ) on 15 October 2021 and the supplementary prospectus issued by Artrya and lodged with ASIC on 10 November 2021 (together, the Prospectus ).

Capitalised terms used but not defined in this announcement have the meaning given to them in the Prospectus.

The following information is provided as pre-quotation disclosure.

Escrow arrangements

Certain Existing Shareholders have entered into mandatory escrow and voluntary escrow arrangements in relation to the Shares and Options they hold.

Mandatory escrow

The total number of Shares subject to mandatory escrow is 21,386,565 and the total number of Options subject to mandatory escrow is 12,000,000.

The mandatory escrow restrictions apply to Shares as follows:

Number of Shares	Mandatory escrow period
15,610,470 Shares	Until 24 months from quotation of Artrya’s Shares on ASX
5,183,961 Shares	Until 19 April 2022
592,134 Shares	Until 23 April 2022

The mandatory escrow restrictions apply to Options as follows:

Number of Options	Mandatory escrow period
12,000,000 Options	Until 24 months from quotation of Artrya’s Shares on ASX

Voluntary escrow

The total number of Shares subject to voluntary escrow is 25,168,121. The voluntary escrow restrictions apply to Shares as follows:

Number of Shares	Voluntary escrow period
25,168,121 Shares	The voluntary escrow period ends on the date that is 12 months after admission of the Company to the official list of the ASX and quotation of the Company’s Shares on ASX

Artrya Limited ABN 53 624 005 741 Suite 14A Level 3 88 Broadway Crawley WA 6009 Australia www.artrya.com

Artrya’s capital structure

Artrya’s capital structure as at the date of this announcement is as follows:

Class	Number of securities
Shares	78,247,590
Options
Escrowed Options exercisable at $0.001 on or before 25 March 2024	6,000,000
Escrowed Options exercisable at $1.00 on or before 23 April 2026	500,000
Escrowed Options exercisable at $1.00 on or before 9 July 2026	5,500,000
Options exercisable at $0.075 on or before 10 January 2025	405,000
Options exercisable at $0.056 on or before 23 September 2025	1,300,000
Options exercisable at $0.075 on or before 27 November 2025	220,000
Options exercisable at $0.075 on or before 31 December 2025	1,226,752
Total Options	15,151,752

On 18 November 2021, Dr Julien Flack exercised 135,000 Options. These Options had vested and were exercisable at $0.075 on or before 10 January 2025. The exercise of these Options has resulted in an increase of 135,000 Shares on issue and a decrease of 135,000 Option on issue (as against the numbers disclosed in the Prospectus).

ASX waivers

Artrya has received the following waivers and confirmations from ASX:

• confirmation that the terms of Artrya’s Performance Options (as defined in the Supplementary Prospectus dated 10 November 2021) are appropriate and equitable for the purpose of ASX Listing Rule 6.1; and

• a waiver from ASX Listing Rule 1.1 condition 12 to the extent necessary to permit Artrya to have the Performance Options (each of which have a nominal exercise price) on issue on the condition that the material terms and conditions of the Performance Options are clearly disclosed in the Prospectus.

Documents enclosed for release to the market

Enclosed for release to the market are the following documents:

• Artrya’s Appendix 1A and Information Form and Checklist;

• the Prospectus, including the Supplementary Prospectus;

• Artrya’s Constitution;

• Artrya’s audited accounts for the full years ended 30 June 2020 and 30 June 2021;

• full terms and conditions of Artrya’s Employee Option Plan 2019

• full terms and conditions of Artrya’s Employee Option Plan 2021

• Artrya’s corporate governance statement;

• Artrya’s securities trading policy;

• a distribution schedule of the number of holders of Shares; and

• a statement setting out the names of the 20 largest Shareholders.

This announcement was approved by the Company’s Managing Director, John Barrington, on behalf of the Artrya Board.

For further information please contact

Investor Enquiries: Media Enquiries: John Barrington Felicity Heath Artrya Limited Daymark 0419 850 502 0457 196 603 investors@artrya.com felicity.heath@daymark.com.au